NCT00132054View on ClinicalTrials.gov

Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

December 31, 2006

Study Completion Date

November 30, 2008

Conditions
Lung Cancer
Interventions
DRUG

amrubicin hydrochloride

DRUG

irinotecan hydrochloride

Trial Locations (7)

373-0828

Gunma Cancer Center, Gunma

070-0901

National Hospital Organization - Dohoku National Hospital, Hokkaido

606-8501

Kyoto University Hospital, Kyoto

530-8480

Kitano Hospital, Osaka

543-0035

Osaka Police Hospital, Osaka

553-0003

Osaka Kosei Nenkin Hospital, Osaka

591-8555

National Hospital Organization - Osaka National Hospital, Osaka

All Listed Sponsors
lead

Japan Multinational Trial Organization

OTHER

NCT00132054 - Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter